Glanbia half-year revenue rises 7%, lifts outlook

Glanbia hikes profit forecast as weight-loss drugs boost demand for protein products

By Padraic Halpin DUBLIN, Aug 6 (Reuters) - Nutrition supplement maker Glanbia hiked its full-year profit forecast on Thursday following bumper demand for its protein products, including from ​customers using them in tandem with weight-loss drugs.

Glanbia raises profit guidance after bumper H1 results

Irish nutrition firm Glanbia has raised its annual profit guidance after posting a strong set of first-half (H1) results.

Glanbia half-year revenue rises 7%, lifts outlook

Nutrition supplement maker Glanbia has today reported higher revenues and profits for the six months to the end of June and said it was upgrading its full year guidance.

Protein demand drives Glanbia revenues and earnings growth

Glanbia has reported a 7% increase in group revenues and 14.1% EBITDA growth for the half-year. The Kilkenny-based food and nutrition group made sales of $2.1bn in the first six months of the year, up from $1.9bn in H1 2025. EBITDA of $275.4m represented an improvement on earnings of $241.3m during the same period last year. Adjusted earnings per share jumped 30% from 63.03c to 81.24c while basic earnings per share were up 66.8% from 39.04c to 6…

Glanbia adjusts earnings per share 'ahead of expectations'

Glanbia plc has announced its 2026 half year results for the six month period ending on July 4 (HY2026). The business said that it has updated its earnings per share (EPS) to 81.24 US cent, “ahead of expectations”. Its EPS outlook for the full year 2026 (FY2026) has been upgraded to between 17% to 20% […] The post Glanbia adjusts earnings per share ‘ahead of expectations’ appeared first on Agriland.ie.